secwatch.observer — SEC 8-K summary
======================================

Issuer:     Aldeyra Therapeutics, Inc. (ALDX)
CIK:        0001341235
Form:       8-K
Filed at:   2023-12-19T23:59:59+00:00
Accession:  0001157523-23-001841
Event type: other_material
Sentiment:  positive
Materiality: 0.70
Item codes: 7.01, 8.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Aldeyra announces positive Phase 2 data for ADX-629 in atopic dermatitis; advancing ADX-246
--------------------------------------------------------------------------------

- Phase 2 trial of ADX-629 in 8 mild-to-moderate atopic dermatitis patients showed statistically significant improvement from baseline in EASI (p=0.0006) and IGA (p<0.0001).
- Three patients (38%) achieved EASI-75; one patient (13%) had complete clearance of affected body surface area; two patients (25%) reported elimination of itching.
- Only two mild treatment-related adverse events reported; no serious adverse events or discontinuations. All eight patients completed the trial.
- Company plans to initiate a randomized placebo-controlled Phase 1/2 trial of ADX-246 in H1 2024, with topline results expected in H2 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1341235/000115752323001841/0001157523-23-001841-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1341235/000115752323001841/a53872843.htm
  HTML page:      https://secwatch.observer/filing/0001157523-23-001841

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer